In Pivotal Phase III Studies, Merck’s Investigational Medicine Boceprevir Helped Majority of Patients with Chronic Hepatitis C Genotype 1 Infection Achieve Sustained Virologic Response, the Primary ...

Your bookshelves (online or real) may be full of medical texts and online articles. Still, it never hurts to have another series of invaluable resources to round out your library. The Merck Manual of ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that BELSOMRA® (suvorexant) is now available at pharmacies in the United States ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new analyses from studies of sotatercept, Merck’s novel investigational activin ...

-- Company will focus on process development and improvements for manufacturing Baylor's Covid-19 vaccine candidates DARMSTADT, Germany, May 27, 2020 /PRNewswire/ -- Merck, a leading science and ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck today reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been ...

Merck (MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data ...

NEW ORLEANS — A new medicine represents a dramatic advance for patients with a rare condition called pulmonary arterial hypertension — and a return to heart disease for Merck, which long had a ...

Merck's plans for a new cholesterol medicine have hit another snag. The drugmaker said yesterday it may have to wait until 2013 to provide enough data to satisfy federal regulators about the ...

ORLANDO, Fla. -- A study released Sunday raises fresh concerns about Zetia and its cousin, Vytorin — drugs still taken by millions of Americans to lower cholesterol, despite questions raised last year ...

Merck (MRK) closed the most recent trading day at $110.99, moving +2.2% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.01%. Meanwhile, the Dow experienced a rise ...

Merck made its decision to withdraw its popular pain-killer Vioxx after studies revealed a small but persistent increase in the risk of heart attack for people using Vioxx rather than its close ...